-
Briumvi®
Briumvi® (ublituximab-xiiy) is a monoclonal antibody infusion therapy approved for the treatment of relapsing forms of multiple sclerosis. At Singlepoint Healthcare, we offer Briumvi® IV therapy as part of a comprehensive care strategy designed to reduce disease activity, preserve neurological function, and help patients maintain independence and quality of life.
How Briumvi® Works
Briumvi® works by selectively targeting CD20-positive B cells. These immune cells play a key role in the inflammatory processes that damage nerve fibers in MS.
By reducing the number of overactive B cells, Briumvi® helps reduce inflammatory attacks on the central nervous system. This targeted approach is designed to lower relapse rates, reduce new disease activity seen on imaging, and slow long-term progression.
Key Details
Important Information
| Category | Details |
|---|---|
| Conditions It Treats | |
| Manufacturer | TG Therapeutics |
| Administered by | Infusion |
| Frequency | Every 24 weeks |
| Length of Infusion | 1 hour |
| FDA Approval(s) | Multiple Sclerosis (MS): Approved December 28, 2022 |